Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Buy

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Qiagen NV (QGEN)

https://www.qiagen.com

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/28/1996

Market Cap

10,331,414,790

Shares Outstanding

228,040,000

Weighted SO

228,182,263

Total Employees

N/A

Upcoming Earnings

07/31/2024

Similar Tickers

NEOG --.--%

OLK --.--%

ACRS --.--%

SYNH --.--%

IQV --.--%

MEDP --.--%

ICLR --.--%

SHC --.--%

AKU --.--%

Beta

0.4000

Last Div

1.3196

Range

34.74-46.63

Chg

0.1400

Avg Vol

1064564

Mkt Cap

10331414790

Exch

NYSE

Country

NL

Phone

31 77 355 6600

DCF Diff

-75.2980

DCF

121.7580

Div Yield

0.0283

P/S

5.3249

EV Multiple

27.6454

P/FV

3.0359

Div Yield %

2.8336

P/E

142.2110

PEG

19.0895

Payout

0.0000

Current Ratio

1.7681

Quick Ratio

1.4572

Cash Ratio

0.5156

DSO

71.0736

DIO

120.2307

Op Cycle

191.3044

DPO

28.4223

CCC

162.8821

Gross Margin

0.4966

Op Margin

0.0874

Pretax Margin

0.0503

Net Margin

0.0375

Eff Tax Rate

0.2548

ROA

0.0130

ROE

0.0200

ROCE

0.0373

NI/EBT

0.7452

EBT/EBIT

0.5753

EBIT/Rev

0.0874

Debt Ratio

0.2510

D/E

0.4116

LT Debt/Cap

0.2107

Total Debt/Cap

0.2916

Int Coverage

3.6329

CF/Debt

0.4108

Equity Multi

1.6400

Rec Turnover

5.1355

Pay Turnover

12.8420

Inv Turnover

3.0358

FA Turnover

2.7031

Asset Turnover

0.3474

OCF/Share

2.5936

FCF/Share

1.8254

Cash/Share

4.0103

OCF/Sales

0.2967

FCF/OCF

0.7038

CF Coverage

0.4108

ST Coverage

1.1686

CapEx Coverage

3.3761

Div&CapEx Cov

3.3761

P/BV

3.0359

P/B

3.0359

P/S

5.3249

P/E

142.2110

P/FCF

25.4963

P/OCF

17.9559

P/CF

17.9559

PEG

19.0895

P/S

5.3249

EV Multiple

27.6454

P/FV

3.0359

DPS

1.3196

Latest Headlines (EST)

GlobeNewswire Inc. Feb 26, 01:30 Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™. GlobeNewswire Inc. Feb 18, 23:30 Pancreatic Cancer Diagnostic Market to Reach $3.2 billion, Globally, by 2035 at 5.9% CAGR: Allied Market Research GlobeNewswire Inc. Oct 04, 03:30 Onco-hematology Molecular Testing Market Size to Reach USD 1.5 billion by 2031 with a 12.5% CAGR, Boosted by Next-Generation Blood Cancer Diagnostics| Exclusive Report by Transparency Market Research, Inc. GlobeNewswire Inc. Sep 13, 00:30 Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights GlobeNewswire Inc. Aug 24, 18:35 Global Cancer Biomarkers Market to Surge from USD 22.78 Billion in 2023 to USD 82.66 Billion by 2033, Achieving a CAGR of 13.76% GlobeNewswire Inc. Jul 26, 13:51 Microbial Detection Systems Market Insights and Forecast, 2024-2032 - BD, Danaher, Thermo Fisher Scientific, bioMerieux, QIAGEN, and Shimadzu Account for ~44% Total Market Share GlobeNewswire Inc. Jul 10, 05:10 Global Multiplex Assay Market Size to Hit $4.40 billion by - GlobeNewswire GlobeNewswire Inc. Jun 03, 06:00 QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care GlobeNewswire Inc. Jun 03, 06:00 QIAGEN erweitert QIAstat-Dx-Menü in den USA mit syndromischem Test für bessere Versorgung bei Magen-Darm-Erkrankungen Benzinga Jan 17, 15:21 Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion GlobeNewswire Inc. Jan 11, 07:53 QIAGEN N.V. to release results for Q4 2023 and hold webcast GlobeNewswire Inc. Jan 08, 02:00 QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems GlobeNewswire Inc. Jan 08, 02:00 QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems GlobeNewswire Inc. Jan 08, 02:00 QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems GlobeNewswire Inc. Jan 07, 13:13 QIAGEN gibt Pläne zur Rückzahlung von rund $300 Mio. an Aktionärinnen und Aktionäre bekannt GlobeNewswire Inc. Jan 07, 13:13 QIAGEN gibt Pläne zur Rückzahlung von rund $300 Mio. an Aktionärinnen und Aktionäre bekannt GlobeNewswire Inc. Jan 07, 13:13 QIAGEN gibt Pläne zur Rückzahlung von rund $300 Mio. an Aktionärinnen und Aktionäre bekannt GlobeNewswire Inc. Jan 07, 13:13 QIAGEN gibt Pläne zur Rückzahlung von rund $300 Mio. an Aktionärinnen und Aktionäre bekannt GlobeNewswire Inc. Jan 07, 13:13 QIAGEN gibt Pläne zur Rückzahlung von rund $300 Mio. an Aktionärinnen und Aktionäre bekannt GlobeNewswire Inc. Jan 07, 13:13 QIAGEN gibt Pläne zur Rückzahlung von rund $300 Mio. an Aktionärinnen und Aktionäre bekannt

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
1.28 01/30/2024 01/22/2024 01/31/2024 01/31/2024
1.08 01/25/2017 01/18/2017 01/26/2017 01/25/2017
0.00 12/26/2002 11/30/-0001 11/30/-0001 11/30/-0001